Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  231.15
-1.38 (-0.59%)
AAPL  272.72
-0.36 (-0.13%)
AMD  215.05
-0.29 (-0.13%)
BAC  55.10
-0.18 (-0.32%)
GOOG  314.37
-0.18 (-0.06%)
META  661.66
-4.29 (-0.64%)
MSFT  485.13
-2.35 (-0.48%)
NVDA  187.75
+0.22 (0.11%)
ORCL  195.80
-1.41 (-0.71%)
TSLA  451.61
-2.82 (-0.62%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.